Scientists test 'One-Two Punch' Gene-Edited cell therapy for tough blood cancers
NCT ID NCT07451054
Summary
This early-stage study is testing the safety of a new two-part treatment for adults with aggressive blood cancers that have returned or not responded to other therapies. First, doctors give patients their own genetically modified stem cells to rebuild their immune system. Then, they receive specially engineered immune cells (CAR T cells) designed to target and fight the cancer. The main goal is to find a safe dose and see if this combined approach is feasible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.